int230-6
intensity therapeutics
['int230-6']
today we announced preliminary data from the phase 1/2 study of our #inkt agonist, port-2, presented at #asco22. we also highlighted presentations from studies of port-1 (int230-6) in collaboration with learn more here: 
Portage Biotech is developing first-in-class immuno-oncology therapies to help more patients achieve durable treatment responses and a better quality of life.